Abstract
We thank Drs. Kahn and Goitein for their interest in reading the November 2005 Supplement to CHEST, entitled “Improving Outcomes in Respiratory Failure: Ventilation, Blood Use, and Anemia Management” 1 Improving outcomes in respiratory failure: ventilation, blood use and anemia management. Chest. 2005; 128: 547S-604S Google Scholar and for taking the time to comment on it. Because the publication was supported by an educational grant from a pharmaceutical company, Drs. Kahn and Goitein have expressed concerns that the Journal “acquires a financial conflict of interest that casts doubt on its editorial independence” and “supplements such as these erode the confidence of the readers in the scientific objectivity of the editors.” Pharmaceutical Industry Sponsorship of Journal SupplementsCHESTVol. 129Issue 5PreviewThe November 2005 Supplement to CHEST, “Improving Outcomes in Respiratory Failure: Ventilation, Blood Use, and Anemia Management,” contained eight review articles1,2,3,4,5,6,7,8 concerning transfusion medicine. Publication was supported by an educational grant from Ortho Biotech, the manufacturer of recombinant human erythropoietin (epoetin). Not surprisingly, the articles are not supportive of transfusion: five articles1,4,5,6,8 discuss the risks of blood transfusion in respiratory failure, and three articles1,4,5 mention epoetin as an attractive alternative. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
